Computational Analysis of Tinospora Cordifolia Phytochemicals as Potential Inhibitors of BRCA1-BRCT Domain Interaction in Breast Cancer

Year : 2025 | Volume : 03 | Issue : 01 | Page : 27-37
    By

    Vaishnavi Rajendra Bendkhale,

  1. Student, Department of Bioinformatics, Savitribai Phule Pune University, Pune, Maharashtra, India

Abstract

Breast cancer is a leading cause of cancer-related deaths worldwide, accounting for a significant proportion of mortality rates among women. Despite current therapeutic approaches, the disease remains characterized by molecular heterogeneity, making it challenging to develop effective treatments. This study explores the potential of Tinospora cordifolia, a medicinal plant, in breast cancer therapy. Guduchi, scientifically known as Tinospora cordifolia, boasts a centuries-long history of use in traditional medicine, with a substantial body of research investigating its anti-cancer properties. Using a computational approach, several phytocompounds with potential anti-cancer properties were identified from Tinospora cordifolia. These compounds exhibited favorable pharmacological properties, including lipophilicity, solubility, and bioavailability, making them suitable for further development. Moreover, molecular docking studies revealed that these compounds had high binding affinity to the BRCT protein, a critical component of the BRCA1 gene. Mutations in the BRCA1 gene, which is vital for DNA repair, have been linked to a heightened risk of developing breast cancer. The identification of Tinospora cordifolia-derived phytocompounds with potential anti-cancer properties is a significant finding, offering a promising avenue for the development of novel cancer treatments. The potential of these compounds as therapeutic agents is promising, making them suitable lead molecules for further research and development. This study demonstrates the potential of Tinospora cordifolia in breast cancer therapy and highlights the importance of exploring traditional medicinal plants as a source of novel anti-cancer agents. Additional research is necessary to uncover the full therapeutic potential of these compounds and to translate this knowledge into effective breast cancer treatments.

Keywords: Breast cancer, BRCA1, BRCA2, T. cordifolia, guduchi, medicinal plants, cancer treatment, molecular docking, pharmacological studies, drug development, herbal medicine, oncology

[This article belongs to International Journal of Molecular Biotechnological Research ]

How to cite this article:
Vaishnavi Rajendra Bendkhale. Computational Analysis of Tinospora Cordifolia Phytochemicals as Potential Inhibitors of BRCA1-BRCT Domain Interaction in Breast Cancer. International Journal of Molecular Biotechnological Research. 2025; 03(01):27-37.
How to cite this URL:
Vaishnavi Rajendra Bendkhale. Computational Analysis of Tinospora Cordifolia Phytochemicals as Potential Inhibitors of BRCA1-BRCT Domain Interaction in Breast Cancer. International Journal of Molecular Biotechnological Research. 2025; 03(01):27-37. Available from: https://journals.stmjournals.com/ijmbr/article=2025/view=202276



Browse Figures

References

  1. Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. The lancet oncology. 2001 Mar 1;2(3):133–40.
  2. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019 Dec 1;5(1):66.
  3. Valastyan S, Weinberg RA. Tumor metastasis: Molecular insights and evolving paradigms. Cell. 2011 Oct 14;147(2):275–92.
  4. Deng CX. BRCA1: Cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic acids research. 2006 Jan 1;34(5):1416–26.
  5. Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic. J Clin Oncol. 2001 Apr 15;19(8):2247–53.
  6. Balmana J, Diez O, Rubio IT, Cardoso F, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2011 Sep 1;22:vi31–4.
  7. Paluch-Shimon S, Cardoso F, Sessa C, Balmaña J, Cardoso MJ, Gilbert F, et al. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Annals of Oncology. 2016 Sep 1;27:v103–10.
  8. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003 Oct 24;302(5645):643–6.
  9. Rana V, Thakur K, Sood R, Sharma V, Sharma TR. Genetic diversity analysis of Tinospora cordifolia germplasm collected from northwestern Himalayan region of India. J Genet.. 2012 Apr 1;91(1):99.
  10. Saeed M, Naveed M, Leskovec J, Kakar I, Ullah K, Ahmad F, et al. Using Guduchi (Tinospora cordifolia) as an eco-friendly feed supplement in human and poultry nutrition. Poultry science. 2020 Feb 1;99(2):801–11.
  11. Clapperton JA, Manke IA, Lowery DM, Ho T, Haire LF, Yaffe MB, et al. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. Nature structural & molecular biology. 2004 Jun 1;11(6):512–8.
  12. Manke IA, Lowery DM, Nguyen A, Yaffe MB. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science. 2003 Oct 24;302(5645):636–9.
  13. Williams RS, Green R, Glover JM. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Mol Biol. 2001 Oct 1;8(10):838–42.
  14. Kozlov SV, Graham ME, Jakob B, Tobias F, Kijas AW, Tanuji M, et al. Autophosphorylation and ATM activation: additional sites add to the complexity. J Biol Chem. 2011 Mar 18;286(11):9107–19. Available from: http://doi.org/10.1074/jbc.M110.204065.
  15. Lee J, Kumagai A, Dunphy WG. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. Mol Biol Cell. 2001 Mar 1;12(3):551–63.
  16. Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science. 2002 Nov 15;298(5597):1435–8.
  17. Ford, B. Betty Ford Speaks Out on Breast Cancer. McCall’s, 1974;101(6):106–107.
  18. King MC. The race” to clone BRCA1. Science. 2014 Mar 28;343(6178):1462–5.
  19. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England journal of medicine. 2001 Mar 15;344(11):783–92.
  20. Singh SS, Pandey SC, Srivastava S, Gupta VS, Patro B, Ghosh AC. Chemistry and medicinal properties of Tinospora cordifolia (Guduchi). Indian J Pharmacol. 2003 Mar 1;35(2):83–91.
  21. Hussain L, Akash MS, Ain NU, Rehman K, Ibrahim M. The analgesic, anti-inflammatory and anti-pyretic activities of tinospora cordifolia. Adv Clin Exp Med. 2015 Nov–Dec;24(6):957–64. doi: 10.17219/acem/27909.
  22. Haldar PK, Bera S, Panda SP, Bhattacharya S, Chaulya NC, Mukherjee A. Hepatoprotective activity of Cyperus tegetum rhizome against paracetamol-induced liver damage in rats. J Complement Integr Med. 2011 Jan;8. Available from: http://doi.org/10.2202/1553-3840.1398.
  23. Chiang CC, Li YR, Lai KH, Cheng WJ, Lin SC, Wang YH, et al. Aqueous extract of kan-lu-hsiao-tu-tan ameliorates collagen-induced arthritis in mice by inhibiting oxidative stress and inflammatory responses. Life (Basel). 2020 Nov 27;10(12):313. Available from: http://doi.org/10.3390/life10120313.
  24. Salehi B, Ata A, V. Anil Kumar N, Sharopov F, Ramírez-Alarcón K, Ruiz-Ortega A, et al. Antidiabetic potential of medicinal plants and their active components. Biomolecules. 2019 Sep 30;9(10):551.
  25. Tiwari R, Latheef SK, Ahmed I, Iqbal HM, Bule MH, Dhama K, et al. Herbal immunomodulators-a remedial panacea for designing and developing effective drugs and medicines: current scenario and future prospects. Current Drug Metab. 2018 Mar 1;19(3):264–301.
  26. Burley SK, Berman HM, Kleywegt GJ, Markley JL, Nakamura H, Velankar S. Protein Data Bank (PDB): The single global macromolecular structure archive. Methods Mol Biol. 2017;1607:627-641. Available from: http://doi.org/1007/978-1-4939-7000-1_26
  27. Chi S, She G, Han D, Wang W, Liu Z, Liu B. Genus Tinospora: Ethnopharmacology, phytochemistry, and pharmacology. Evid Based Complement Alternat Med. 2016;2016:9232593. Available from: http://doi.org/10.1155/2016/9232593.
  28. Bhati S, Kumar V, Singh S, Singh J. Synthesis, characterization, antimicrobial, anti-tubercular, antioxidant activities and docking simulations of derivatives of 2-(pyridin-3-yl)-1Hbenzo [d] imidazole and 1, 3, 4-oxadiazole analogy. Lett Drug Des Discov. 2020 Aug 1;17(8):1047–59.
  29. Rai P, Garain T, Gupta D. Phytochemical analysis of Tinospora cordifolia and Withania somnifera and their therapeutic activities with special reference to COVID-19. World J Exp Med. 2024 Sep 20;14(3):95512. doi: 10.5493/wjem.v14.i3.95512.
  30. Choi EJ, Lee JI, Kim GH. Evaluation of the anticancer activities of thioflavanone and thioflavone in human breast cancer cell lines. Int J Mol Med. 2012 Feb;29(2):252–6. doi: 10.3892/ijmm.2011.834.
  31. Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, et al. PubChem in 2021: New data content and improved web interfaces. Nucleic acids research. 2021 Jan 8;49(D1):D1388–95.
  32. Alchab F, Ali A, Maya R. Design of novel HIV-1 protease inhibitors with favorable oral properties using a molecular modelling approach. Res J Pharm Technol 2024 Aug 26 3836–42.
  33. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific reports. 2017 Mar 3;7(1):42717.
  34. Lipinski CA. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol. 2004 Dec 1;1(4):337–41.
  35. Dallakyan S, Olson AJ. Small-molecule library screening by docking with PyRx. Chemical Biology: Methods and Protocols. 2015:243–50.
  36. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: An open chemical toolbox. Journal of Cheminformatics. 2011 Dec;3:1–4.
Regular Issue Subscription Original Research
Volume 03
Issue 01
Received 27/12/2024
Accepted 21/02/2025
Published 28/02/2025
Publication Time 63 Days
Total Visits: 56


My IP

PlumX Metrics